There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CymaBay Therapeutics (CBAY) and Lipocine (LPCN) with bullish sentiments.
CymaBay Therapeutics (CBAY)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on CymaBay Therapeutics, with a price target of $23. The company’s shares closed on Friday at $9.66.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 10.7% and a 38.2% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CymaBay Therapeutics with a $19.33 average price target, representing a 100.1% upside. In a report issued on November 7, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $17 price target.
.
See today’s analyst top recommended stocks >>
Lipocine (LPCN)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Lipocine, with a price target of $3. The company’s shares closed on Friday at $1.44, close to its 52-week low of $1.03.
According to TipRanks.com, Livnat is a 3-star analyst with an average return of 2.4% and a 50.0% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
The the analyst consensus on Lipocine is currently a Hold rating.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
